IDYA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

33.445

Open

32.020

VWAP

32.70

Vol

694.23K

Mkt Cap

2.88B

Low

31.910

Amount

22.70M

EV/EBITDA(TTM)

--

Total Shares

87.81M

EV

2.24B

EV/OCF(TTM)

--

P/S(TTM)

13.29

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Show More

Events Timeline

(ET)

2026-03-30

06:10:00

Ideaya Biosciences Launches IDE849 Clinical Trial

2026-03-23 (ET)

2026-03-23

10:30:00

Ideaya Biosciences Updates Guidance on OptimUM-02 Trial Data Release

2026-03-23

10:10:00

Ideaya Biosciences Shares Down 6.0% to $30.79

2026-03-09 (ET)

2026-03-09

06:10:00

Ideaya Biosciences Enrolls First Patient in IDE892 Clinical Trial

2026-02-25 (ET)

2026-02-25

06:20:00

Ideaya Biosciences Enrolls First Patient in IDE034 Clinical Trial

2026-02-23 (ET)

2026-02-23

06:10:00

Ideaya Biosciences Appoints Theodora Ross as Chief Development Officer

2026-02-17 (ET)

2026-02-17

06:10:00

Ideaya Biosciences Reports Q4 Revenue of $10.88M

News

PRnewswire

03-30PRnewswire

IDEAYA Biosciences Initiates Phase 1 Clinical Trial for IDE849 and IDE161

Newsfilter

03-30Newsfilter

IDEAYA Biosciences Advances Clinical Trials for IDE849 and IDE161

PRnewswire

03-27PRnewswire

IDEAYA Grants 49,000 Stock Options to New Employees

Newsfilter

03-27Newsfilter

IDEAYA Grants Stock Options to New Employees

seekingalpha

03-23seekingalpha

IDEAYA Biosciences Delays Data Release for Eye Cancer Trial

PRnewswire

03-22PRnewswire

IDEAYA Biosciences Announces Upcoming Investor Relations Events

15 Analyst Rating

Wall Street analysts forecast IDYA stock price to rise

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

49.86

High

79.00

Current: 0.000

Low

30.00

Averages

49.86

High

79.00

Citi

Buy

maintain

$65

AI Analysis

2026-03-06

Reason

Citi

Price Target

$65

AI Analysis

2026-03-06

maintain

Buy

Reason

Citi placed an "upside 90-day catalyst watch" on shares of Ideaya Biosciences while keeping a Buy rating on the name with a $65 price target. Citi sees a favorable share setup into the Phase 2/3 data OptimUM-02 trial expected in late March in HLA*A2-negative metastatic uveal melanoma.

Citi

Buy

maintain

$64 -> $65

2026-02-19

Reason

Citi

Price Target

$64 -> $65

2026-02-19

maintain

Buy

Reason

Citi raised the firm's price target on Ideaya Biosciences to $65 from $64 and keeps a Buy rating on the shares. The firm is positive on the shares into the OptimUM-02 readout at the end of March.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IDYA

Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is 4.65, compared to its 5-year average forward P/E of -10.39. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-10.39

Current PE

4.65

Overvalued PE

-4.67

Undervalued PE

-16.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-7.94

Current EV/EBITDA

-2.67

Overvalued EV/EBITDA

1.19

Undervalued EV/EBITDA

-17.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

89.88

Current PS

23.60

Overvalued PS

183.69

Undervalued PS

-3.93

Financials

AI Analysis

Annual

Quarterly

Whales Holding IDYA

Deerfield Management Company, L.P.

Sofinnova Investment, Inc.

Tang Capital Management, LLC

Baker Bros. Advisors LP

General American Investors Company, Inc.

Logos Global Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is IDEAYA Biosciences Inc (IDYA) stock price today?

The current price of IDYA is 32.74 USD — it has increased 0.8

What is IDEAYA Biosciences Inc (IDYA)'s business?

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

What is the price predicton of IDYA Stock?

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?

IDEAYA Biosciences Inc revenue for the last quarter amounts to 10.88M USD, increased 55.37

What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?

IDEAYA Biosciences Inc. EPS for the last quarter amounts to -0.94 USD, decreased -36.91

How many employees does IDEAYA Biosciences Inc (IDYA). have?

IDEAYA Biosciences Inc (IDYA) has 145 emplpoyees as of April 03 2026.

What is IDEAYA Biosciences Inc (IDYA) market cap?

Today IDYA has the market capitalization of 2.88B USD.